# A Study of AP402 in HER2-Positive Patients With Locally or Advanced Solid Tumors

Source: https://onco.cc/trials/nct06669975/  
OnCo record `nct06669975` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of AP402 (Part 1 Dose esclation) in advanced solid tumours, run by AP Biosciences Inc., now recruiting.

## Summary

A Study of AP402 in HER2-Positive Patients With Locally or Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT06669975 by AP Biosciences Inc., with 85 participants planned, started 2025-04-22 and due to reach its primary completion in 2026-12-01. Interventions recorded: AP402 (Part 1 Dose esclation) and AP402 (Part 2 Dose Expansion).

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06669975
- Phase: 1/2
- Setting: A Phase 1/2, Open-label Study of the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Clinical Activity of AP402 in HER2-Positive Patients With Locally or Advanced Solid Tumors
- Sponsor: AP Biosciences Inc.
- Enrolled: 85

## Sources

- ClinicalTrials.gov NCT06669975: https://clinicaltrials.gov/study/NCT06669975

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- companies: [AP Biosciences](https://onco.cc/companies/ap-biosciences/)

---
JSON: https://onco.cc/api/v1/entities/nct06669975.json